KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Work In Process (2017 - 2020)

Amneal Pharmaceuticals has reported Work In Process over the past 4 years, most recently at $53.1 million for Q1 2020.

  • Quarterly results put Work In Process at $53.1 million for Q1 2020, changed N/A from a year ago — trailing twelve months through Mar 2020 was $53.1 million (changed N/A YoY), and the annual figure for FY2019 was $58.2 million, up 7.45%.
  • Work In Process for Q1 2020 was $53.1 million at Amneal Pharmaceuticals, down from $58.2 million in the prior quarter.
  • Over the last five years, Work In Process for AMRX hit a ceiling of $59.2 million in Q2 2018 and a floor of $38.1 million in Q4 2017.
  • Median Work In Process over the past 4 years was $52.1 million (2018), compared with a mean of $50.4 million.
  • Biggest five-year swings in Work In Process: surged 41.96% in 2018 and later crashed 35.13% in 2019.
  • Amneal Pharmaceuticals' Work In Process stood at $38.1 million in 2017, then surged by 41.96% to $54.2 million in 2018, then rose by 7.45% to $58.2 million in 2019, then fell by 8.79% to $53.1 million in 2020.
  • The last three reported values for Work In Process were $53.1 million (Q1 2020), $58.2 million (Q4 2019), and $50.8 million (Q3 2019) per Business Quant data.